List view / Grid view
3 December 2015 | By Victoria White
NICE has published draft guidance as part of its highly specialised technologies programme that does not recommend Alexion’s asfotase alfa for treating paediatric-onset hypophosphatasia...
23 November 2015 | By Victoria White
The positive draft guidance follows the development of a managed access scheme by BioMarin and NHS England...
19 November 2015 | By Victoria White
The new Cancer Drugs Fund will become an instrument for the collection of important information on longer term benefits which may not be available at the time of licensing...
19 November 2015 | By Victoria White
NICE’s FAD coincides with a period of great uncertainty with the Cancer Drugs Fund deliberating again whether to remove radium-223 from the list...
18 November 2015 | By Victoria White
The NICE Committee felt the question whether Repatha (evolocumab) would reduce angina, heart attacks and strokes remains unanswered...
17 November 2015 | By Victoria White
NICE has published final draft guidance not recommending the use of Kadcyla as a treatment for a type of advanced breast cancer because the price is too high...
4 November 2015 | By Victoria White
Ikervis has been recommended for the treatment of keratitis in adults with dry eye disease who have not responded to tear substitutes...
28 October 2015 | By Victoria White
Tolavptan is the first-ever treatment shown to slow progression of the life-threatening condition...
21 October 2015 | By Victoria White
The new draft guidance is different to the original 2007 guidance because it reflects the fact that current clinical practice has a greater emphasis on managing CVD risk rather than meeting target cholesterol levels...
19 October 2015 | By Victoria White
Viekirax and Exviera are the first treatments for chronic HCV to combine three direct-acting antiviral agents to target the infection at multiple steps in the viral lifecycle...
